Honduras vs Tunisia: Average cost of multi drug-resistant tuberculosis treatment
Honduras
3,743 constant 2022 US$
in 2024
Tunisia
4,560 constant 2022 US$
in 2023
Honduras rank
11th
Tunisia rank
9th
Average cost of multi drug-resistant tuberculosis treatment over time
- Honduras
- Tunisia
How they compare
Tunisia currently reports 4,560 constant 2022 US$ against 3,743 constant 2022 US$ in Honduras, a difference of 817 constant 2022 US$.
That makes Tunisia's figure about 1.2 times Honduras's.
Across all 6 years both countries report, Tunisia has been ahead every year.
Honduras ranks 11th and Tunisia ranks 9th of 92 countries.
Tunisia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Honduras | Tunisia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,862 constant 2022 US$ | 4,150 constant 2022 US$ | 2,288 constant 2022 US$ | Tunisia |
| 2020s | 1,428 constant 2022 US$ | 3,665 constant 2022 US$ | 2,237 constant 2022 US$ | Tunisia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Honduras or Tunisia?
- Tunisia, at 4,560 constant 2022 US$ against 3,743 constant 2022 US$ in Honduras as of 2023.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Honduras and Tunisia?
- 817 constant 2022 US$, with Tunisia ahead.
- How many years of comparable data are there for Honduras and Tunisia?
- 6 years are reported by both, from 2017 to 2023.
- How do Honduras and Tunisia rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Honduras ranks 11th and Tunisia ranks 9th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.